WAT
FY2026 Q1 · Calendar Q2 2026
Waters Corporation
Waters Corporation delivered a decisive first-quarter beat, with revenue of $1.267 billion (13% organic growth) and adjusted EPS of $2.70 (+20% YoY), both above the high end of guidance and consensus. The stock surged over 13% on the report. Management raised full-year organic revenue guidance to 6.5-8% from ~5.3% and EPS to $14.40-$14.60 from $14.30-$14.50, reflecting early traction on BD integration synergies and broad-based instrument demand. The acquisition of BD's Biosciences and Diagnostic Solutions business is already generating $35 million in revenue synergies through cross-selling and pricing actions. Key regulatory milestones -- FDA clearance for an HPV self-collection kit and CE marking for the BACTEC FXI system ahead of schedule -- position Waters for continued product-driven growth. The prior quarter's tone of confident integration preparation has shifted to confident…
EPS surprise+16.9%
Market move+13.5%
